Abstract
Chih Ying Lin, Ta‐Wei Guu, Hsueh‐Chou Lai, Cheng‐Yuan Peng, Jill Yi-Ju Chiang, Huiting Chen, Tsai‐Chung Li, Shing-Yu Yang, Kuan‐Pin Su, Jane Pei‐Chen Chang
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Chronic hepatitis C virus infection and depression
10.1016/j.cld.2017.03.007 · 2017
Brain moderators supporting the relationship between depressive mood and pain
10.1097/j.pain.0000000000001595 · 2019
Pain perception threshold in major depression
10.1016/0006-3223(93)90041-b · 1993
Interferon-combination strategies for the treatment of chronic hepatitis C
10.1055/s-0034-1371008 · 2014
Depression and pain comorbidity: a literature review
10.1001/archinte.163.20.2433 · 2003
The impact of somatic symptoms on the course of major depressive disorder
10.1016/j.jad.2016.06.030 · 2016
Differential associations of specific depressive and anxiety disorders with somatic symptoms
10.1016/j.jpsychores.2014.11.007 · 2015
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions
10.1016/s0893-133x(01)00407-9 · 2002
Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection
10.1080/1028415x.2015.1123378 · 2017
Association of changes in mood status and psychosocial well-being with depression during interferon-based treatment for hepatitis C
10.4306/pi.2017.14.3.314 · 2017
The epidemiology of multiple somatic symptoms
10.1016/j.jpsychores.2012.01.009 · 2012
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
10.7326/0003-4819-107-2-293 · 1987
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial
10.4088/jcp.09m05282blu · 2011
The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?
10.1016/j.antiviral.2014.02.005 · 2014
The association of chronic pain and suicide
1999
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy
10.1016/s0168-8278(01)00280-x · 2002
The relationship of presenting physical complaints to depressive symptoms in primary care patients
10.1007/bf02598007 · 1992
Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study
10.1016/s0163-8343(02)00239-6 · 2003
Anti-viral therapy and decreased sexual desire in patients with chronic hepatitis C
10.1371/journal.pone.0160450 · 2016
A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C
10.1016/j.jpsychores.2014.07.020 · 2015
Gender and symptoms in primary care practices
10.1176/appi.psy.44.5.359 · 2003
Significance of somatic complaints in patients suffering from psychotic depression
10.1159/000285676 · 1963
Somatic symptoms in depression
10.31887/dcns.2006.8.2/hpkapfhammer · 2006
Somatic symptoms in primary care: etiology and outcome
10.1176/appi.psy.44.6.471 · 2003
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684
10.1200/jco.1996.14.1.7 · 1996
Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management
10.1002/mpr.140 · 2003
Symptoms in the community: prevalence, classification, and psychiatric comorbidity
10.1001/archinte.1993.00410210102011 · 1993
Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment
10.1001/archfami.3.9.774 · 1994
Pain perception in psychiatric disorders: a review of the literature
10.1016/0022-3956(94)90023-x · 1994
The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI
10.1016/s0924-9338(97)83296-8 · 1997
Pro- and anti-inflammatory cytokine associations with major depression in cancer patients
2016
Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study
10.1016/j.jpsychores.2012.10.012 · 2013
Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C
10.1089/107999001300177457 · 2001
Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?
10.1016/j.jad.2013.01.020 · 2013
Using chronic pain to predict depressive morbidity in the general population
10.1001/archpsyc.60.1.39 · 2003
The Mini-International Neuropsychiatric Interview is useful and well accepted as part of the clinical assessment for depression and anxiety in primary care: a mixed-methods study
10.1186/s12875-017-0674-5 · 2018
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction
10.4088/jcp.v66n0106 · 2005
Neuropsychiatric adverse effects of interferon-alpha: recognition and management
10.2165/00023210-200519020-00002 · 2005
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C
10.1111/j.1365-2036.2007.03316.x · 2007
Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement
10.1016/j.jhep.2012.07.037 · 2012
Association of somatic symptoms with depression and anxiety in clinical patients of general hospitals in Guangzhou, China
10.1016/j.genhosppsych.2011.09.005 · doi-reference
Hepatitis C and depression
10.1002/(sici)1520-6394(1998)7:4<188::aid-da7>3.0.co;2-6 · doi-reference
The relationship between pain and depression
10.1192/s0007125000298474 · doi-reference
Treatment of neurotoxic side effects of interferon-alpha with naltrexone
10.3109/07357909509024923 · doi-reference
Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis
10.4088/jcp.13r08800 · doi-reference
The level of recognition of physical symptoms in patients with a major depression episode in the outpatient psychiatric practice in Puerto Rico: an observational study
10.1186/1471-244x-5-28 · doi-reference
Interferon-alpha-induced depression: comparisons between early- and late-onset subgroups and with patients with major depressive disorder
10.1016/j.bbi.2019.04.032 · doi-reference
Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon-alpha-induced depression
10.7603/s40681-015-0021-x · doi-reference
Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a ’mind-body interface’?
10.1159/000198167 · doi-reference
The role played by depression associated with somatic symptomatology in accounting for the gender difference in the prevalence of depression
10.1007/s00127-012-0540-7 · doi-reference
The validity of the Mini international neuropsychiatric interview (MINI) according to the SCID-P and its reliability
10.1016/s0924-9338(97)83297-x · doi-reference
Psychological and behavioral variables associated with the somatic symptom severity of general hospital outpatients in China
10.1016/j.genhosppsych.2012.11.001 · doi-reference
Interferon alpha (IFNalpha) and psychiatric syndromes: a review
10.1016/s0278-5846(01)00324-4 · doi-reference